Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 8,770 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $621.29, for a total value of $5,448,713.30. Following the completion of the transaction, the chief executive officer directly owned 515,153 shares in the company, valued at approximately $320,059,407.37. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Medpace Stock Down 0.2%
Shares of MEDP stock opened at $615.18 on Friday. The firm has a 50 day moving average of $584.38 and a 200-day moving average of $509.80. The company has a market cap of $17.17 billion, a price-to-earnings ratio of 36.06, a price-to-earnings-growth ratio of 2.75 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Medpace
Institutional Investors Weigh In On Medpace
A number of institutional investors and hedge funds have recently bought and sold shares of MEDP. BlackRock Inc. purchased a new stake in Medpace in the 2nd quarter valued at about $1,323,047,000. Madison Asset Management LLC purchased a new position in shares of Medpace in the 2nd quarter worth approximately $128,956,000. Bank of America Corp DE bought a new position in shares of Medpace in the second quarter valued at approximately $116,891,000. American Capital Management Inc. bought a new position in shares of Medpace in the second quarter valued at approximately $111,329,000. Finally, Franklin Resources Inc. increased its position in shares of Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after acquiring an additional 183,645 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
About Medpace
Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.
Featured Stories
- Five stocks we like better than Medpace
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
